Advertisement

FDA Update: New Hot Flash Treatment, Olmesartan Warning, OC Pill Recall — Physician’s First Watch

Medical News |
July 8, 2013

FDA Update: New Hot Flash Treatment, Olmesartan Warning, OC Pill Recall

By Amy Orciari Herman

Here's a quick look at what the FDA was up to while we were away last week:

New hot flash therapy: The agency approved the first nonhormonal treatment for hot flashes in menopausal women. Brisdelle contains 7.5 mg of paroxetine, lower than the doses used to treat depression, anxiety, and other psychiatric conditions. The pill is taken once daily at bedtime. Like other formulations of paroxetine, Brisdelle's label includes a boxed warning noting an increased risk for suicidality.

Olmesartan warning: The antihypertensive medication olmesartan, an angiotensin-receptor blocker marketed as Benicar, Azor, and others, can cause spruelike enteropathy, the FDA warned. Providers should counsel patients to contact them if severe diarrhea with substantial weight loss occurs, even if symptoms develop years after starting the drug.

Estarylla recall: One lot of the combination oral contraceptive Estarylla (norgestimate and ethinyl estradiol) has been recalled after a consumer found a placebo pill in a row of active tablets. The lot number is LF01213A.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement